louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01397045: Fast Track Rehabilitation Following Video-assisted Lung Segmentectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Multiple Pulmonary Nodules
Keywords: Lung
Nodule
Rehabilitation
VATS
Thoracotomy
Lead sponsor: Theagenio Cancer Hospital
Sponsor class: OTHER_GOV
First posted: 2011-07-19
Enrollment: 120
Sex: ALL
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Aim of this prospective randomized study is to assess the safety and efficacy of video-assisted lung segmentectomy (Group B) comparing with mini muscle-sparing thoracotomy (group A) during diagnostic process for pulmonary nodules.


Eligibility criteria: Inclusion Criteria:

* Patients with undiagnosed multiple pulmonary nodules

Exclusion Criteria:

* Centrally located lesions
* previous thoracotomy
* extensive lung consolidation, and inability to achieve one lung ventilation

Primary outcomes:
measure: Duration of hospital stay
timeFrame: Participants will be followed till home discharge, an average of 2 weeks
Secondary outcomes:
measure: postoperative morbidity
timeFrame: Participants will be followed till home discharge, an average of 2 weeks
Other outcomes:
Locations:
city: Thessaloniki
country: Greece
facility: Thoracic Surgery Department, Theagenio Cancer Hospital
Study officials:
References:
Clinical trial NCT00377845: Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear.
Official title: Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Uterine Cervical Dysplasia
Uterine Cervical Neoplasms
Keywords: self test
PAP smear
tampon test
cervical dysplasia
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2006-09-19
Enrollment: 100
Sex: FEMALE
Minimum age (years): 23
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SCREENING

Brief summary: The purpose of this study is to compare suitability, specificity and sensitivity of the routine smear and the tampon self-test women perform at home.

Study hypothesis: The tampon self-test correspond to the routine cervical smear.


Eligibility criteria: Inclusion Criteria:

1. Women with cervical dysplasia been referred to conisation or
2. Women invited to cervical screening program

Exclusion Criteria:

1. Women not performing the tampon self-test before conisation or
2. Women not performing the tampon self-test af least 1 month after receiving the tampon

Primary outcomes:
measure: Sensitivity and specificity of the tampon self-test
Secondary outcomes:
measure: The womens socio-demographic relations according to accept the tampon self-test
Other outcomes:
Locations:
city: Randers
country: Denmark
facility: Region Hospital Randers
Study officials:
affiliation: Randers Hospital, Pathological Institute
name: Hans Svanholm, consultant
role: STUDY_DIRECTOR
References:
Clinical trial NCT05924945: Impact of Bridge™ Device to Treat Opioid Withdrawal Symptoms
Official title: Impact of Bridge™ Device as a Non-pharmacological Approach to Treat Opioid Withdrawal in Opioid Use Disorder (OUD) Subjects in an Inpatient Treatment Center
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Opioid Use Disorder
Lead sponsor: Masimo Corporation
Sponsor class: INDUSTRY
First posted: 2023-06-29
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this prospective study is to investigate the efficacy of the Bridge™ device in reducing the symptoms of opioid withdrawal in a blind comparison to a sham device.


Eligibility criteria: Inclusion Criteria:

* Participant able to provide written informed consent
* Participant is 18 to 65-years old
* Participant has confirmed opioid use disorder (OUD) as defined by the Diagnostic and Statistical Manual of Mental Disorders-5
* Participants is entering an OUD treatment program

Exclusion Criteria:

* Participant requires tapering from another substance at entry to treatment
* Participant is pregnant or lactating
* Participant has a history of hemophilia or psoriasis vulgaris
* Participant has a cardiac pacemaker implant device
* Participant has irritated or broken skin at the site of intended device placement
* Participant is currently participating in, or was enrolled in another clinical trial within the last 30 days
* Participant has a history of poor wound healing
* Participant has a severe autoimmune disease or uncontrolled diabetes
* Participant has an open wound/abscess infection/MRSA
* Participant has a history of a chronic pain in the last 90 days
* Participant has a serious medical condition which in the judgment of the principal investigator or his/her designee would make study participation unsafe, or would make intervention compliance difficult
* Participant has a psychiatric illness (bipolar disorder, schizophrenia, or other psychotic disorder, active suicidal ideation with a plan within the last month or suicide attempt)

Primary outcomes:
measure: Assess change in Clinical Opiate Withdrawal Scale (COWS) score
timeFrame: pre-device placement to Day 5 (post-device removal)
Secondary outcomes:
measure: Assess change in Subjective Opiate Withdrawal Scale (SOWS) score
timeFrame: pre-device placement to Day 5 (post-device removal)
Other outcomes:
Locations:
city: Wernersville
country: United States
facility: Caron Treatment Centers
state: Pennsylvania
Study officials:
References:
Clinical trial NCT00877045: Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting
Official title: Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Gastrointestinal Stromal Tumors
Keywords: Gastrointestinal Stromal Tumors
GIST
tyrosine kinase inhibitors
Imatinib
Gleevec
Suntinib
Sutent
Lead sponsor: SCRI Development Innovations, LLC
Sponsor class: OTHER
Collaborators: name: Pfizer
First posted: 2009-04-07
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients diagnosed with GIST based on ICD-9 code from January 2005 to present will be eligible. This will include current active patients as well as patients who have expired and have medical chart available. Estimate reviewing approximately 300 charts total.

Brief summary: This is a retrospective medical record abstraction to evaluate the patterns of care for Gastrointestinal stromal tumors (GIST) in the community setting. Patient demographics and characteristics along with the treatments received will be described. Investigators will establish the percentage of patients who undergo surgery, the percentage of patients who are treated with kinase inhibitors as well as in what setting (adjuvant or metastatic) as well as the duration of therapy. Physician information will also be collected to assess for differences in treatment based on physician or geographical differences.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with GIST based on ICD-9 code from January 2005 to present will be eligible. This will include current active patients as well as patients who have expired and have medical chart available.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Fort Myers
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Atlanta
country: United States
facility: Georgia Cancer Specialists
state: Georgia
city: Chattanooga
country: United States
facility: Chattanooga Oncology Hematology Associates
state: Tennessee
city: Nashville
country: United States
facility: Tennessee Oncology, PLLC
state: Tennessee
city: Richmond
country: United States
facility: Virginia Cancer Institute
state: Virginia
Study officials:
affiliation: SCRI Development Innovations, LLC
name: Jeffrey F Patton, M.D.
role: STUDY_CHAIR
References:
Clinical trial NCT04835545: Work of Breathing Under Extreme Hypercapnia Induced by Ventilation Insufficiency
Official title: Work of Breathing Under Extreme Hypercapnia Induced by Ventilation Insufficiency
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Accident Caused by Snow Avalanche
Keywords: snow
avalanche
hypercapnia
work of breathing
Lead sponsor: Czech Technical University in Prague
Sponsor class: OTHER
First posted: 2021-04-08
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of the study is to investigate Work of Breathing of a person in simulated avalanche snow and consequent use of the measured data for judging which one of three simulated scenarios are alike while increasing hypercapnia in the simulated avalanche snow.

Detailed description: The study is a part of a university diploma thesis aimed at studying physiological conditions and development of breathing parameters of a person breathing in the simulated avalanche snow. The Investigator is measuring Work of Breathing in three scenarios: a) 2L air pocket, b) 2L air pocket with resistance compensation and c) no air pocket. The investigator hypothesize that the Work of Breathing during compensation of air pocket will be alike with no air pocket scenario, thus proving significance of the resistance reduction for survival. The aim of the study is to investigate the effect of Work of Breathing on gas exchange in subjects breathing into the simulated avalanche snow scenarios.

Eligibility criteria: Inclusion Criteria:

* healthy and fit volunteers, classified as The American Society of Anesthesiologists class I
* without a smoking history

Exclusion Criteria:

* Tiffeneau Index less than 0.70
* any cardiovascular or respiratory condition

Primary outcomes:
measure: The length of breathing
timeFrame: Continuously within up to 7 minute interval from the beginning of the breathing experiment
Secondary outcomes:
Other outcomes:
Locations:
city: Kladno
country: Czechia
facility: Czech Technical University, Faculty of Biomedical Engineering
Study officials:
affiliation: Czech Technical University in Prague, FBMI
name: Karel Roubík, PhD
role: STUDY_DIRECTOR
References:
citation: Roubik K, Sieger L, Sykora K. Work of Breathing into Snow in the Presence versus Absence of an Artificial Air Pocket Affects Hypoxia and Hypercapnia of a Victim Covered with Avalanche Snow: A Randomized Double Blind Crossover Study. PLoS One. 2015 Dec 14;10(12):e0144332. doi: 10.1371/journal.pone.0144332. eCollection 2015.
Clinical trial NCT03793205: G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients
Official title: Long-acting Granulocyte Colony Stimulating Factor for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients: A Prospective Cohort Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Gynecologic Cancer
Myelosuppression Adult
Febrile Neutropenia
Chemotherapy-induced Neutropenia
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2019-01-04
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: After the chemotherapy, patients accepted long-acting G-CSF and/or short-acting G-CSF.
Primary purpose: TREATMENT

Brief summary: This study aims to analyze the effects of long-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in gynecologic cancer patients. Patients all accepted platinum-based chemotherapy 3-4 weeks once per course. The primary end is the incidence of FN in every course of chemotherapy. After the chemotherapy, patients accepted long-acting G-CSF and/or short-acting G-CSF. The secondary ends include: the incidences of myelosuppression, doses of G-CSF and its expenses, visits to outpatient and emergency clinics, adverse events related to G-CSF.


Eligibility criteria: Inclusion Criteria:

* Confirmed primary gynecologic cancer
* Good performance status
* Aged 18 years or older
* Signed an approved informed consents
* No immunosuppressive disease

Exclusion Criteria:

* Not meeting all of the inclusion criteria

Primary outcomes:
measure: Incidence of febrile neutropenia
timeFrame: One year
Secondary outcomes:
measure: Incidences of grade 3/4 myelosuppression
timeFrame: One year
measure: Times of visits to outpatient and emergency clinics
timeFrame: One year
measure: Doses of G-CSF
timeFrame: One year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Lei Li
state: Beijing
Study officials:
References:
Clinical trial NCT03433105: Oxygen Uptake in Weaning of Patients From Prolonged Mechanical Ventilation
Official title: To Investigate the Prognostic Value of Oxygen Uptake in Weaning of Patients From Prolonged Mechanical Ventilation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Ventilator Weaning
Keywords: oxygen uptake
prolonged mechanical ventilation
weaning
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2018-02-14
Enrollment: 157
Sex: ALL
Minimum age (years): 20
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patient who have tracheostomy tubes and with prolonged mechanical ventilation

Brief summary: 1.Research hypothesis: during weaning patient from prolonged mechanical ventilation, if the work load caused by weaning was below the patient's AT, oxygen uptake will be constant. Otherwise, if the work load was above the patient's AT, the oxygen uptake will increase.

1. Patient: who have tracheostomy tubes and with prolonged mechanical ventilation
2. Measurement: oxygen uptake(V̇O2) and respiratory mechanics during the spontaneous breathing trials
3. Outcome: Correlation between the oxygen uptake(V̇O2) and the weaning outcome

2.Specific aims:

1. to investigate the prognostic value of oxygen uptake in weaning patients from prolonged mechanical ventilation
2. Subgroup analysis may suggest which weaning protocol potentially benefit the most for each population group (cardiovascular disease, chronic pulmonary disease, neuromuscular disease, cerebrovascular disease)


Eligibility criteria: 1. Inclusion criteria:

   Adult \>20 y/o Total duration of mechanical ventilation ≥ 10 days Received tracheostomy Defervescence Meeting the criteria of weaning phase (see supplementary protocols)
2. Exclusion criteria FiO2 \>50 % Unstable hemodynamics Fever with active infection No spontaneous respiratory drive Dynamic airway collapse

Primary outcomes:
measure: Measurement of oxygen uptake (V̇O2)
timeFrame: up to 12 hours during the spontaneous breathing trial
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Yao-Wen Kuo, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06549205: Effects of Trigeminal Neurostimulation on Heart Rate Variability: Comparing Tragus and Tongue Stimulation.
Official title: Effects of Trigeminal Neurostimulation on Heart Rate Variability: Comparing Cutaneous (Tragus) and Tongue (Antero-Dorsal Mucosa) Stimulation.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Arousal, Confusional
Keywords: Trigeminal electrical stimulation
ULFTENS
Heart rate variability
tragus
tongue
Lead sponsor: University of L'Aquila
Sponsor class: OTHER
First posted: 2024-08-12
Enrollment: 80
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: this study wants to analyse the effect of trigeminal stimulation on Heart rate Variability. There are going to be two groups, in the test group it will be administered stimulation of the tongue with TENS, while in the control goup TENS will be administered at tragus level.

Detailed description: This study analyses the effect of trigeminal stimulation with TENS on Heart rate variability (HRV). A new intraoral device will be administered on the dorsal surface of the tongue for TENS stimulation in the test group. The RMSSD, LF, HF and LF/HF will be monitered by photoplethysmographic wave. the results obtained with tongue stimulation will be compared with the results obtained in the control group, where it will be administered TENS stimulation at the tragus level. This work sought to assess whether there is a difference in HRV in relation to the site of application of dental ULFTENS (tragus vs tongue).

If effective in reducing the activity of arousal circuits, this tongue-level stimulation technique could have new clinical applications.

Eligibility criteria: Inclusion Criteria:

* Healthy Women
* Age 18-30 years

Exclusion Criteria:

* presence of acute and/or chronic cardio-circulatory and respiratory disorders
* metabolic and autonomic system disorders
* intake of excitatory or inhibiting substances of the peripheral and central nervous system
* presence of generalised anxiety and/or panic attacks or mood disorders.

Primary outcomes:
measure: Changes on Low Frequency parameter (LF)
timeFrame: 12 minutes
measure: Changes on Root mean square standard deviation (RMSSD) parameter
timeFrame: 12 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: L'Aquila
country: Italy
facility: Sara Di Nicolantonio
Study officials:
References:
Clinical trial NCT05897905: Improving Follow up Care for People After Minor Stroke
Official title: A Feasibility Study Investigating an Early, Personalised, Follow-up Programme for People After Minor Stroke
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Stroke, Acute
Keywords: Secondary prevention
Adjustment to life after stroke
Hidden impairments
Cognition
Mood
Fatigue
Lead sponsor: Imperial College Healthcare NHS Trust
Sponsor class: OTHER
First posted: 2023-06-09
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The goal of this feasibility study is to ascertain if this follow-up programme of care can feasibly be implemented within a healthcare system with people after minor stroke.

The main feasibility questions are:

i) To establish recruitment uptake ii) To establish treatment adherence iii) To determine participant retention. Participants will be randomly allocated to the intervention and control group. Those in the intervention group will receive a follow-up telephone call at two weeks after discharge and a second follow-up appointment at six weeks after discharge. Outcome measures will be taken at twelve weeks after discharge.


Eligibility criteria: Inclusion Criteria:

* Adult ≥18
* Clinical or radiological diagnosis of minor stroke from a stroke consultant.
* Admitted to HASU or seen in rapid assessment/TIA clinic.
* Pre-admission mRS of 0-3 with no formal package of care prior to stroke.
* Discharge mRS of 0-3.
* No onward referral to community therapy team or for package of care.
* Has capacity to consent.

Exclusion Criteria:

* Any serious co-morbidities that would impact a person's ability to participate in the follow-up appointments and outcome measurement.
* Insufficient English to engage in intervention and outcome measures and no family or friends to support with this.
* Not resident in England.
* Pregnant women.

Primary outcomes:
measure: Recruitment rate
timeFrame: Baseline
measure: Treatment completion rate
timeFrame: 6 weeks post randomisation
measure: Retention rate
timeFrame: 12 weeks post randomisation
Secondary outcomes:
measure: PROMIS10
timeFrame: 2 weeks and 12 weeks
measure: Health Care Climate Questionnaire Short Form
timeFrame: Baseline and 12 weeks
measure: MOCA
timeFrame: Baseline and 12 weeks
measure: PHQ9
timeFrame: 12 weeks
measure: GAD7
timeFrame: 12 weeks
Other outcomes:
measure: Qualitative interviews
timeFrame: 13 weeks
Locations:
city: London
country: United Kingdom
facility: Imperial College Healthcare NHS Trust
Study officials:
affiliation: Imperial College Healthcare NHS Trust
name: Jennifer Crow
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01942005: EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients
Official title: EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients,Especially Patients After Organ Transplantation and Patients With HIV Infection
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Immunosuppression
Neoplasm
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2013-09-13
Enrollment: 144
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients who underwent organ transplatation or patients who have a HIV infection

Brief summary: Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.

Detailed description: correlation between possibly detected mutation/specific polymorphism and kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression.

Eligibility criteria: Inclusion Criteria:

* patients in an immunosuppressive condition either by immunosuppressants or by HIV infection

Exclusion Criteria:

* written informed consent not given

Primary outcomes:
measure: Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.
timeFrame: 7 years
Secondary outcomes:
measure: correlation between possibly detected mutation/specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen and a composite of kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression.
timeFrame: 7 years
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: University Hospital Basel, Dermatology
state: Basel Stadt
Study officials:
affiliation: University Hospital Basel, Dermatology, CH-4031 Basel
name: Andreas Arnold, MD
role: PRINCIPAL_INVESTIGATOR
References: